Clinical trial NCT03581825: Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population
Official title: Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Visual Acuity
Lead sponsor: Johnson & Johnson Vision Care, Inc.
Sponsor class: INDUSTRY
First posted: 2018-07-10
Enrollment: 63
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a single-masked, randomized-controlled, dispensing clinical trial. A total of approximately 60 eligible myopic subjects will be targeted to complete the study.


Eligibility criteria: Inclusion Criteria:

* Potential subjects must satisfy all the following criteria to be enrolled in the study:

  1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  3. The subject must be between 40 and 70 years of age (inclusive).
  4. The subject's distance spherical equivalent refraction must be in the range of -1.25 D to -3.75 D in each eye.
  5. The subject's refractive cylinder must be ≤0.75 D in each eye.
  6. The subject's ADD power must be in the range of +0.75 D to +2.50 D.
  7. The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye.
  8. Subjects must own a wearable pair of spectacles if required for their distance vision.
  9. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration).
  10. The subject must either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".

      Exclusion Criteria:
* Potential subjects who meet any of the following criteria will be excluded from participating in the study:

  1. Currently pregnant or lactating.
  2. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
  3. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
  4. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
  5. Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma, history of recurrent corneal erosions.
  6. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).
  7. A history of amblyopia, strabismus or binocular vision abnormality.
  8. Any current ocular infection or inflammation.
  9. Any current ocular abnormality that may interfere with contact lens wear.
  10. Use of any of the following oral medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral antihistamines (e.g., Chlor-Trimeton, and Benadryl), systemic steroids.
  11. Use of any ocular medication, with the exception of rewetting drops.
  12. History of herpetic keratitis.
  13. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
  14. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
  15. Any known hypersensitivity or allergic reaction to Optifree®Replenish® multipurpose care solution or Eye-Cept® rewetting drop solution.

Primary outcomes:
measure: CLUE Vision
timeFrame: 2-Week Follow-up
Secondary outcomes:
measure: CLUE Vision Comparison Between Test and Control
timeFrame: 2-Week Follow-up
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Coughlin Eye Center
state: Florida
city: East Lansing
country: United States
facility: VisionCare Associates
state: Michigan
city: Raytown
country: United States
facility: Eyecare Management Company, LLC
state: Missouri
city: Jamestown
country: United States
facility: Jamestown Optometric Group
state: New York
city: Vestal
country: United States
facility: Susquehanna Eye Care
state: New York
city: Tyler
country: United States
facility: Bryan Frazier, OD
state: Texas
Study officials:
References: